Kuntz Richard 4

What Happened

• Richard Kuntz, a director of DiaMedica Therapeutics Inc. (DMAC), was granted a derivative award of 40,412 shares on 2026-06-01. The filing reports an acquisition price of $0.00 (award/compensation), so no cash purchase occurred. This is an award/vesting grant rather than a market purchase or sale.

Key Details

• Transaction date: 2026-06-01; Form 4 filed: 2026-06-03 (appears timely — filed two days after the transaction).
• Transaction type/code: A (Grant/Award, derivative).
• Shares granted: 40,412 shares at $0.00 (reported value $0 in the filing).
• Post-transaction ownership: not specified in the provided excerpt of the filing.
• Footnote: F1 — shares are scheduled to vest in four equal quarterly installments.
• No 10b5-1 plan, sale, or tax-withholding details reported in the excerpt.

Context

• This was a compensation-related award (derivative/unvested shares). Because the shares vest over time, they are subject to forfeiture until vested and do not represent an immediate market purchase or sale. Such awards are common for directors and reflect compensation policy rather than a direct buy or sell signal.